Compare GFL Environmental Inc. Subordinate voting shares no par value (GFL) vs Revolution Medicines Inc. Common Stock (RVMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GFL Environmental Inc. Subordinate voting shares no par value vs Revolution Medicines Inc. Common Stock — how do they compare? GFL Environmental Inc. Subordinate voting shares no par value trades at $42.84 (market cap $18.46B), while Revolution Medicines Inc. Common Stock trades at $189.76 (market cap $40.32B). The key difference: Revolution Medicines Inc. Common Stock is far larger — about 2.2× GFL Environmental Inc. Subordinate voting shares no par value's market cap, and GFL Environmental Inc. Subordinate voting shares no par value pays a 0.16% dividend while Revolution Medicines Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold GFL Environmental Inc. Subordinate voting shares no par value for 1 Days and Revolution Medicines Inc. Common Stock for 0 Days on average.
| GFL | RVMD | |
|---|---|---|
Market Cap | $18.46B | $40.32B |
Volume | 2,438,353 | 4,855,734 |
Sector | Industrials | Health |
52-Week High | $46.51 | $221.15 |
52-Week Low | $33.54 | $47.50 |
Typical Hold Time | 1 Days | 0 Days |
Enterprise Value | $25.43B | $37.02B |
Dividend Yield | 0.16% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About GFL Environmental Inc. Subordinate voting shares no par value
GFL Environmental provides environmental services across Canada and the United States. Its operations include solid waste management and other waste and environmental solutions.
Read more on GFL →About Revolution Medicines Inc. Common Stock
Revolution Medicines develops precision medicines for cancer. Its programs focus on targeting RAS-driven cancers and related signaling pathways.
Read more on RVMD →
